Candel Therapeutics Inc (CADL) - News Archive

Candel Therapeutics: A Trailblazer in Cancer Immunotherapy with Promising Outcomes in Glioblastoma and Prostate CancerCandel Therapeutics, Inc. (Nasdaq: CADL), a pioneering clinical-stage biopharmaceutical company, cont...

Candel Therapeutics Appoints Pancreatic Cancer Expert Amid Struggles: A New Chapter or an Uphill Battle?NEEDHAM, Mass.—In a move that signals both promise and urgency, Candel Therapeutics, Inc. (Nasdaq: CADL), a clinica...

Candel Therapeutics, a clinical-stage biopharmaceutical company, has made significant strides in the fight against cancer with the recent announcement of their Phase 3 trial results for CAN-2409, a novel viral immunothe...

Candel Therapeutics, Inc. a clinical-stage biopharmaceutical company based in Needham, Massachusetts, continues to make strides in the fight against cancer. On December 12, 2024, the company announced the pricing of an...

Candel Therapeutics, Inc. a clinical-stage biopharmaceutical company, has made significant strides in the development of its multimodal biological immunotherapies for cancer treatment. Recent announcements about preclin...

In the rapidly advancing field of oncology, Candel Therapeutics, Inc. (Nasdaq: CADL), emerges as a beacon of innovation and hope. With a steadfast commitment to developing multimodal biological immunotherapies, the clin...

Candel Therapeutics Inc (NASDAQ: CADL) has been a point of interest for investors and analysts alike over the past few weeks, marked by notable fluctuations in stock performance and significant insider trading activity....

Candel Therapeutics Inc. has emerged as a leading player in the pharmaceutical industry, gaining recognition for its innovative cancer therapies. Despite facing financial challenges, the company has managed to outperfor...

Candel Therapeutics Inc Shares Face Challenges Amidst a Strong Performance This YearCandel Therapeutics Inc, a pharmaceutical company focused on drug discovery, has experienced a challenging year in terms of stock perfo...

China s Domestic Investors Shift Focus Amidst Global Market Volatility While Candel Therapeutics Inc Outperforms Healthcare SectorIn recent developments, China s domestic investors have adjusted their expectations for t...

Candel Therapeutics Joins Russell 3000 Index, Despite Cumulative Net LossCandel Therapeutics, a clinical stage biopharmaceutical company focused on cancer immunotherapies, has announced its inclusion in the broad-market...

Candel Therapeutics, a clinical stage biopharmaceutical company, has recently made significant advancements in the development of multimodal biological immunotherapies to combat cancer. The company s innovative approach...

In a groundbreaking announcement, Candel Therapeutics, Inc., a leading clinical-stage biopharmaceutical company dedicated to advancing multimodal biological immunotherapies to combat cancer, specified two significant ab...

Candel Therapeutics, a clinical-stage biopharmaceutical company focused on the development of innovative multimodal biological immunotherapies, has achieved significant milestones in the treatment of pancreatic and brai...

Candel Therapeutics, a clinical-stage biopharmaceutical firm with a strong emphasis on the development of multimodal biological immunotherapies for cancer patients, recently unveiled preclinical data at the AACR Annual...

In an ongoing stride towards innovative cancer treatments, Candel Therapeutics, Inc. - a clinical stage biopharmaceutical firm committed to developing multimodal biological immunotherapies to counter cancer, recently sh...

Candel Therapeutics, a clinical stage biopharmaceutical company, recently presented updated data from an ongoing phase 1b clinical trial of their viral immunotherapy candidate, CAN-3110, during the 5th Glioblastoma Drug...

Candel Therapeutics, a renowned biotechnology company, has been making significant strides in recent times, propelling itself towards a highly promising future in 2024. With a focus on key value drivers and effective ca...

NEEDHAM, Mass. Candel Therapeutics, a biopharmaceutical company based in Massachusetts, announced a significant milestone in its effort to develop an effective treatment for pancreatic ductal adenocarcinoma (PDAC). The...

Candel Therapeutics Announces Restructuring to Prioritize Resources on Key Value Drivers for Expanded Development of CAN-3110, the enLIGHTEN Discovery Platform, and Key Clinical Readouts for CAN-2409NEEDHAM, Mass., Nov....